This is an interesting view coming from an alternative stem cell developer. Don’t know how much of it to put down to being uncouth and how much to give genuine thought to. His views on the FDA’s concerns with MSBs batch consistency and manufacturing process are jarring. Would be interested to hear others views.
Cell Therapy News/Articles, page-8296
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.018(1.50%) |
Mkt cap ! $1.353B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $3.296M | 2.781M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 23414 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 25412 | 19 |
View Market Depth
| Last trade - 13.44pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |